Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Novacyt S.A. is an international molecular diagnostics company that develops, manufactures, and commercializes a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The company offers molecular assays, workflows, and instrumentation for research and clinical applications, enabling seamless end-to-end solutions from sample to result. Its products support sectors including human health, animal health, and environmental testing, with recognition as a leader in reproductive health, precision medicine, and infectious disease. Business units such as Primerdesign, Microgen Bioproducts, and Lab21 Healthcare provide in vitro and molecular diagnostic tests, assays, and reagents supplied worldwide. Novacyt S.A. maintains offices in France, the United Kingdom, Singapore, the United States, and Canada, serving a commercial presence in over 65 countries. Founded in 2006 and headquartered in Le Vésinet, France, the company plays a key role in advancing clinical diagnostics through innovative genomic solutions.
The business is unprofitable at the operating level (-61.80% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 2.0%, essentially flat. Margins also contracted 78.9pp. This is a business that needs a catalyst.
ROIC dropped from 3.31% to -20.90%, capital efficiency is deteriorating. Negative free cash flow of -£10M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
£20M
▲ +2.0% YoY
Net Income (TTM)
-£23M
▲ +45.2% YoY
Op. Margin
-61.80%
▼ -78.9pp YoY
ROIC
-20.90%
▼ -24.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£10M
▲ +10.2% YoY
Op. Cash Flow (TTM)
-£10M
▼ -112.3% YoY
Net Debt
-£9M
Net Cash Position
Cash & Equiv.
£19M
3Y CAGR: -1.6%
Continue Research